Trial Profile
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Budigalimab (Primary) ; Giloralimab (Primary) ; Giloralimab (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 19 Jan 2024 Planned End Date changed from 10 Feb 2024 to 29 Mar 2024.
- 19 Jan 2024 Planned primary completion date changed from 10 Feb 2024 to 29 Mar 2024.
- 20 Jan 2023 Planned End Date changed from 27 Oct 2022 to 10 Feb 2024.